Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PegIntron + Rebetol for 48 vs 72 weeks in treatment-naive genotype 1 chronic hepatitis C slow responders
2004-000488-83Phase 3Completed
- Sponsor
- Schering AG
- Start
- Oct 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2b and ribavirin in chronic hepatitis C virus infection (2 arms), sponsored by Schering AG. Primary endpoint: Sustained viral response at 24 weeks after end of treatment. Started Oct 2004; status: completed.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
chronic hepatitis C virus infection
Beyond the preview
Go deeper on 2004-000488-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000488-83.